Welcome to our dedicated page for Smith & Nephew Plc SEC filings (Ticker: SNNUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Smith & Nephew Plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Smith & Nephew Plc's regulatory disclosures and financial reporting.
Smith+Nephew has scheduled an expert surgeon insights event for investors and analysts in London on 9 June 2026. The half‑day meeting will highlight key innovation platforms that management expects to drive the next phase of growth under the company’s RISE strategy.
Renowned US surgeons will discuss technologies including the REGENETEN◊ Bioinductive Implant, CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, PICO◊ single use Negative Pressure Wound Therapy System, CORI Surgical System, AETOS◊ Shoulder System, LANDMARK◊ Knee System and the TESSA◊ Spatial Surgery System. The event will be hosted by the Chief Executive Officer, Chief Financial Officer and other senior leaders, with product demonstrations and Q&A sessions. Smith+Nephew notes it generated annual sales of $6.2 billion in 2025 and operates across Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Smith+Nephew has scheduled an expert surgeon insights event for investors and analysts in London on 9 June 2026. The half‑day meeting will highlight key innovation platforms that management expects to drive the next phase of growth under the company’s RISE strategy.
Renowned US surgeons will discuss technologies including the REGENETEN◊ Bioinductive Implant, CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, PICO◊ single use Negative Pressure Wound Therapy System, CORI Surgical System, AETOS◊ Shoulder System, LANDMARK◊ Knee System and the TESSA◊ Spatial Surgery System. The event will be hosted by the Chief Executive Officer, Chief Financial Officer and other senior leaders, with product demonstrations and Q&A sessions. Smith+Nephew notes it generated annual sales of $6.2 billion in 2025 and operates across Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Smith+Nephew, a global medical technology company, has filed a report to confirm the timing of its first quarter 2026 trading update. The company will publish its trading report for the quarter ended 28 March 2026 on 6 May 2026 at 7:00am BST / 2:00am EDT, followed by an analyst conference call at 8:30am BST / 3:30am EDT.
Smith+Nephew focuses on the repair, regeneration and replacement of soft and hard tissue through three business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It operates in more than 100 countries and generated $6.2 billion of annual sales in 2025.
Smith+Nephew, a global medical technology company, has filed a report to confirm the timing of its first quarter 2026 trading update. The company will publish its trading report for the quarter ended 28 March 2026 on 6 May 2026 at 7:00am BST / 2:00am EDT, followed by an analyst conference call at 8:30am BST / 3:30am EDT.
Smith+Nephew focuses on the repair, regeneration and replacement of soft and hard tissue through three business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It operates in more than 100 countries and generated $6.2 billion of annual sales in 2025.
Smith & Nephew plc reported that senior executives received new share awards under its RISE Share Plan. On 15 April 2026, the company granted awards over ordinary shares of US$0.20 each to multiple persons discharging managerial responsibilities, including the Chief Executive Officer and Chief Financial Officer, with each listed executive allocated 50 shares at nil cost. The awards form part of the company’s RISE strategy and were granted under the Smith & Nephew plc RISE Share Plan, a sub-plan of the Smith & Nephew plc Restricted Share Plan 2024.
Smith & Nephew plc reported that senior executives received new share awards under its RISE Share Plan. On 15 April 2026, the company granted awards over ordinary shares of US$0.20 each to multiple persons discharging managerial responsibilities, including the Chief Executive Officer and Chief Financial Officer, with each listed executive allocated 50 shares at nil cost. The awards form part of the company’s RISE strategy and were granted under the Smith & Nephew plc RISE Share Plan, a sub-plan of the Smith & Nephew plc Restricted Share Plan 2024.
Smith & Nephew plc filed a report noting that Thérèse Esperdy, its Senior Independent Director designate, will join the Board of Rentokil Initial plc as a Non-Executive Director and Chair-designate from 1 July 2026, becoming Chair of the Board on 1 September 2026. The company also highlights that it operates in more than 100 countries with $6.2 billion in annual sales in 2025, supported by around 17,000 employees across its orthopaedics, sports medicine & ENT, and advanced wound management businesses.
Smith & Nephew plc filed a report noting that Thérèse Esperdy, its Senior Independent Director designate, will join the Board of Rentokil Initial plc as a Non-Executive Director and Chair-designate from 1 July 2026, becoming Chair of the Board on 1 September 2026. The company also highlights that it operates in more than 100 countries with $6.2 billion in annual sales in 2025, supported by around 17,000 employees across its orthopaedics, sports medicine & ENT, and advanced wound management businesses.
Smith & Nephew plc submitted an amended report to clarify how investors can access its 2025 Annual Report, 2026 AGM materials, and proposed new Articles of Association. The company confirms these documents are on the UK National Storage Mechanism and its website, and that hard copies are available free of charge to shareholders and ADS holders upon request to the Company Secretariat in Watford, England.
Smith & Nephew plc submitted an amended report to clarify how investors can access its 2025 Annual Report, 2026 AGM materials, and proposed new Articles of Association. The company confirms these documents are on the UK National Storage Mechanism and its website, and that hard copies are available free of charge to shareholders and ADS holders upon request to the Company Secretariat in Watford, England.
Smith & Nephew plc reports its updated share capital and voting rights position. As at 31 March 2026, the company has 877,733,750 ordinary shares of US20¢ each in issue, including 23,761,952 held in treasury. The issued share capital with voting rights consists of 853,971,798 ordinary shares, each carrying one vote. Shareholders are directed to use 853,971,798 as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reports its updated share capital and voting rights position. As at 31 March 2026, the company has 877,733,750 ordinary shares of US20¢ each in issue, including 23,761,952 held in treasury. The issued share capital with voting rights consists of 853,971,798 ordinary shares, each carrying one vote. Shareholders are directed to use 853,971,798 as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reported that on 23 March 2026 multiple executive and senior managers had share awards vest under its Global Share Plans 2010/2020 and Restricted Share Plan 2024.
Ordinary shares were delivered and portions sold on the London Stock Exchange at £11.938637 to cover tax liabilities, with the balance retained by each participant.
Smith & Nephew plc reported that on 23 March 2026 multiple executive and senior managers had share awards vest under its Global Share Plans 2010/2020 and Restricted Share Plan 2024.
Ordinary shares were delivered and portions sold on the London Stock Exchange at £11.938637 to cover tax liabilities, with the balance retained by each participant.
Cevian Capital II GP LTD filed Amendment No. 4 to its Schedule 13D on Smith & Nephew plc, reporting beneficial ownership of 81,687,136 ordinary shares, equal to 9.6% of the outstanding shares. Cevian has sole voting and dispositive power over this entire stake.
Cevian states it bought these shares for the Cevian funds for total consideration of about USD $1,095,708,998, funding the purchases from the funds’ general working capital and paying in British pounds, using an exchange rate of USD $1.32385 per GBP 1.00. The 9.6% figure is based on 849,889,305 ordinary shares outstanding as of February 28, 2026, as reported by the issuer on Form 6-K filed on March 2, 2026.
Cevian Capital II GP LTD filed Amendment No. 4 to its Schedule 13D on Smith & Nephew plc, reporting beneficial ownership of 81,687,136 ordinary shares, equal to 9.6% of the outstanding shares. Cevian has sole voting and dispositive power over this entire stake.
Cevian states it bought these shares for the Cevian funds for total consideration of about USD $1,095,708,998, funding the purchases from the funds’ general working capital and paying in British pounds, using an exchange rate of USD $1.32385 per GBP 1.00. The 9.6% figure is based on 849,889,305 ordinary shares outstanding as of February 28, 2026, as reported by the issuer on Form 6-K filed on March 2, 2026.
Smith & Nephew plc submitted a Form 6-K to inform investors that its 2025 Annual Report and related shareholder documents are now available. The company has published the 2025 Annual Report, the Notice of the 2026 Annual General Meeting, the Form of Proxy for the 2026 AGM, and proposed new Articles of Association.
The 2025 Annual Report on Form 20-F was also filed with the SEC on the same day, and all documents are accessible via the UK National Storage Mechanism and the company’s investor relations website.
Smith & Nephew plc submitted a Form 6-K to inform investors that its 2025 Annual Report and related shareholder documents are now available. The company has published the 2025 Annual Report, the Notice of the 2026 Annual General Meeting, the Form of Proxy for the 2026 AGM, and proposed new Articles of Association.
The 2025 Annual Report on Form 20-F was also filed with the SEC on the same day, and all documents are accessible via the UK National Storage Mechanism and the company’s investor relations website.
Smith & Nephew plc filed a Form 6-K stating that it has sent its annual report for fiscal year 2025 to shareholders. The report for the year ended 31 December 2025 is attached as Exhibit 99.1. This filing is primarily administrative, forwarding the full annual report to investors.
Smith & Nephew plc filed a Form 6-K stating that it has sent its annual report for fiscal year 2025 to shareholders. The report for the year ended 31 December 2025 is attached as Exhibit 99.1. This filing is primarily administrative, forwarding the full annual report to investors.